Ray Dalio's TGTX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 586,631 shares of TG Therapeutics, Inc. (TGTX) worth $32.72 M, representing 0.14% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Ray Dalio has maintained this position in TGTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2026, adding 156,727 shares. Largest reduction occurred in Q1 2026, reducing 158,440 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +156,727 | Add 36.46% | 586,631 | $55.78 |
| Q2 2026 | +118,489 | Add 38.05% | 429,904 | $54.94 |
| Q1 2026 | -158,440 | Reduce 33.72% | 311,415 | $33.22 |
| Q4 2025 | +127,706 | Add 37.32% | 469,855 | $29.81 |
| Q3 2025 | +342,149 | New Buy | 342,149 | $36.13 |
Ray Dalio's TG Therapeutics Investment FAQs
Ray Dalio first purchased TG Therapeutics, Inc. (TGTX) in Q3 2025, acquiring 342,149 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held TG Therapeutics, Inc. (TGTX) for 5 quarters since Q3 2025.
Ray Dalio's largest addition to TG Therapeutics, Inc. (TGTX) was in Q3 2025, adding 342,149 shares worth $12.36 M.
According to the latest 13F filing for Q3 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 586,631 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $32.72 M.
As of the Q3 2026 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.14% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in TG Therapeutics, Inc. (TGTX) was 586,631 shares, as reported at the end of Q3 2026.